

A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With Diabetic Macular Edema DME

NCT06908876

Status	RECRUITING
Phase	Phase 2
Sponsor	Innovent Biologics Technology Limited (Shanghai R&D Center)
Enrollment	150 participants

Key Eligibility Criteria

Inclusion (6)

- Informed Consent Form (ICF) must be signed before participating in the study, compliance is good, and willing to complete the visit as planned;
- Subjects aged 18-80 years (inclusive) at the time of screening, and diagnosed with type I or type II diabetes;
- DME involved the macular fovea at screening;
- CSTe320 μ m as confirmed by OCT in the study eye at screening.
- At baseline, visual acuity loss in the study eye due to DME with BCVA ranging from 19 to 78 ETDRS letters (inclusive);
- ... and 1 more (see full listing online)

Exclusion (17)

- High-risk PDR in the study eye;
- Dense hard exudation that destroyed the fovea structure of the macula in the study eye;
- Iris neovascularization in the study eye;
- Other systemic/ocular disease associated with the study eye may cause subjects fail to respond to study treatment or confuse the interpretation of study findings;
- Uncontrolled glaucoma in the study eye; Eye treatment
- ... and 12 more (see full listing online)

Locations (1 total)

Shanghai General hospital, Shanghai, Shanghai Municipality, China